LAMPIT Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Lampit patents expire, and when can generic versions of Lampit launch?
Lampit is a drug marketed by Bayer Healthcare and is included in one NDA.
The generic ingredient in LAMPIT is nifurtimox. One supplier is listed for this compound. Additional details are available on the nifurtimox profile page.
Summary for LAMPIT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 30 |
| Clinical Trials: | 3 |
| Patent Applications: | 7 |
| Drug Prices: | Drug price information for LAMPIT |
| What excipients (inactive ingredients) are in LAMPIT? | LAMPIT excipients list |
| DailyMed Link: | LAMPIT at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for LAMPIT
Generic Entry Date for LAMPIT*:
Constraining patent/regulatory exclusivity:
INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LAMPIT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Drugs for Neglected Diseases | Phase 2 |
| U.S. Food and Drug Administration (FDA) | Phase 2 |
| Institute of Parasitology and Biomedicine Lopez Neyra | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for LAMPIT
US Patents and Regulatory Information for LAMPIT
LAMPIT is protected by zero US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of LAMPIT is See Plans and Pricing.
This potential generic entry date is based on INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting LAMPIT
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-001 | Aug 6, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-002 | Aug 6, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-001 | Aug 6, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-002 | Aug 6, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
